Department of Pharmaceutical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; Department of Competitive Intelligence Research, Beijing Institute of Science and Technology Information, Beijing 100044, China.
Department of Pharmaceutical Sciences, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Int J Pharm. 2020 Aug 30;586:119616. doi: 10.1016/j.ijpharm.2020.119616. Epub 2020 Jul 7.
In this study, toad venom (TV) and realgar were loaded into a poloxamer 188/407 (F127/F188)-based temperature-sensitive in situ gel (TISG) and encapsulated in solid lipid nanoparticles (TV-SLN) or ground nano-realgar (NR) to improve drug release and reduce local irritation after vaginal administration. The combination of TV-SLN and NR (TV-SLN/NR) greatly enhanced the inhibition of tumor cell proliferation and was most effective at a dose ratio of 2:3 (w/w). After TV-SLN/NR treatment, S and G0/G1 phase arrest were observed in HeLa and SKOV-3 cells and the inhibitory effects on proliferation were stronger than those in the conventional powder group. The gelation temperature of TV-SLN and NR-loaded TISG (TV-SLN/NR-TISG) using the selected formulation was 33 ± 0.91 °C. The cumulative release of the drug increased as the dissolution of gel progressed, showing a linear relationship (r > 0.99). TV-SLN/NR-TISG enabled the sustained release of cargo by adhesion to the vaginal mucosa and showed excellent biocompatibility during continuous administration for 7 days. We specifically demonstrated the effectiveness of the TISG for the vaginal delivery of TV-SLN and NR, supporting its important clinical implications for the treatment of cervical cancer.
在这项研究中,蟾酥(TV)和雄黄被载入泊洛沙姆 188/407(F127/F188)为基础的温度敏感原位凝胶(TISG)中,并封装在固体脂质纳米粒(TV-SLN)或纳米雄黄(NR)中,以改善药物释放并减少阴道给药后的局部刺激。TV-SLN 和 NR 的组合(TV-SLN/NR)极大地增强了对肿瘤细胞增殖的抑制作用,在剂量比为 2:3(w/w)时效果最佳。在 TV-SLN/NR 处理后,在 HeLa 和 SKOV-3 细胞中观察到 S 和 G0/G1 期阻滞,并且对增殖的抑制作用强于常规粉末组。使用所选配方的 TV-SLN 和 NR 负载 TISG(TV-SLN/NR-TISG)的胶凝温度为 33 ± 0.91°C。随着凝胶溶解的进行,药物的累积释放增加,呈线性关系(r>0.99)。TV-SLN/NR-TISG 通过粘附在阴道黏膜上实现了货物的持续释放,并在连续给药 7 天期间表现出优异的生物相容性。我们特别证明了 TISG 用于阴道输送 TV-SLN 和 NR 的有效性,这支持了其在宫颈癌治疗中的重要临床意义。